Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cyclophosphamide + Dexamethasone + Lenalidomide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Lenalidomide||Revlimid||IMiD-1||Revlimid (lenalidomide) is a thalidomide analog which regulates cytokine production and stimulates T cells and NK cells activity (PMID: 24328678). Revlimid (lenalidomide) is FDA approved for use in multiple myeloma, relapsed or refractory Mantle cell lymphoma, and in combination with a rituximab product in follicular lymphoma and marginal zone lymphoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||multiple myeloma||not applicable||Cyclophosphamide + Dexamethasone + Lenalidomide||Phase III||Actionable||In a Phase III trial, compared to Thalidomide, Revlimid (lenalidomide), when combined with Cytoxan (cyclophosphamide) and Dexamethasone resulted in better induction response (53% vs 60%), improved progression free survival (32.9 vs 35.9 months), and 3 year overall survival (77.0% vs 82.9%) in multiple myeloma patients (J Clin Oncol 35, 2017 (suppl; abstr 8009)).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|